HEREDITARY ANGIOEDEMA IN MEXICO: ESTIMATING THE ECONOMIC BURDEN AND RESOURCE UTILIZATION IN PUBLIC HEALTHCARE
Author(s)
Mauricio M. Rodriguez, MD1, Eduardo Piñeyro, MD2, Francisco Contreras, MMSc3, Ileana Madrigal, MD4, Andrea Velasco, MD5;
1Takeda Mexico, CDMX, Mexico, 2ISSSTE San Luis Potosí, San Luis Potosí, Mexico, 3National Pediatric Institute, CDMX, Mexico, 4UMAE HE CENTRO MEDICO NACIONAL DE OCCIDENTE. IMSS, Guadalajara, Mexico, 5Hospital Infantil de México, CDMX, Mexico
1Takeda Mexico, CDMX, Mexico, 2ISSSTE San Luis Potosí, San Luis Potosí, Mexico, 3National Pediatric Institute, CDMX, Mexico, 4UMAE HE CENTRO MEDICO NACIONAL DE OCCIDENTE. IMSS, Guadalajara, Mexico, 5Hospital Infantil de México, CDMX, Mexico
OBJECTIVES: To estimate the economic burden (annual direct medical costs to the public healthcare system) of Hereditary Angioedema (HAE) in Mexico and compare healthcare resource utilization and costs between on-demand treatment and long-term prophylaxis from the perspective of the public healthcare system.
METHODS: Systematic literature review and modified Delphi Panel methodology were used to assess the use of resources involved in the diagnosis and treatment of HAE. Costs were taken from institutional sources, particularly the IMSS procurement portal and Diagnosis-Related Groups (DRGs-2017). In this study, economic burden refers to the annual direct medical costs of HAE to the public healthcare system, including diagnosis, acute attack management, and long-term prophylaxis costs. Results are presented as annual-cost per patient with and without long-term prophylaxis.
RESULTS: The cost per diagnosis is 283.93 USD. The estimated annual-cost per patient without long-term prophylaxis after diagnosis is 191,833.86 USD, which includes 100% of the integrated cost for the treatment of HAE attacks. This cost is distributed as follows: 70% (134,732.64 USD) peripheral attacks (facial, tongue and limbs), 28% (54,412.47 USD) abdominal attacks and 1% (2,404.82 USD) laryngeal attacks. The medical costs for attacks are distributed as follows: 37% for treatment, 29% for complications, 15% for hospital stays. In contrast, the annual cost per patient receiving long-term prophylaxis is 105,446.99 USD, with 89% allocated to prophylactic treatment and only 11% to attack management. The Long-term prophylaxis reduces attacks frequency, therefore the related costs by ~94% vs on demand treatment, resulting in a ~45% reduction in total annual direct medical costs per patient.
CONCLUSIONS: HAE imposes a significant economic burden on Mexico’s public healthcare system, primarily due to unpredictable acute attacks. Long-term prophylaxis substantially reduces healthcare costs and improves resource efficiency by reducing the frequency of angioedema attacks supporting its adoption as a cost-effective strategy.
METHODS: Systematic literature review and modified Delphi Panel methodology were used to assess the use of resources involved in the diagnosis and treatment of HAE. Costs were taken from institutional sources, particularly the IMSS procurement portal and Diagnosis-Related Groups (DRGs-2017). In this study, economic burden refers to the annual direct medical costs of HAE to the public healthcare system, including diagnosis, acute attack management, and long-term prophylaxis costs. Results are presented as annual-cost per patient with and without long-term prophylaxis.
RESULTS: The cost per diagnosis is 283.93 USD. The estimated annual-cost per patient without long-term prophylaxis after diagnosis is 191,833.86 USD, which includes 100% of the integrated cost for the treatment of HAE attacks. This cost is distributed as follows: 70% (134,732.64 USD) peripheral attacks (facial, tongue and limbs), 28% (54,412.47 USD) abdominal attacks and 1% (2,404.82 USD) laryngeal attacks. The medical costs for attacks are distributed as follows: 37% for treatment, 29% for complications, 15% for hospital stays. In contrast, the annual cost per patient receiving long-term prophylaxis is 105,446.99 USD, with 89% allocated to prophylactic treatment and only 11% to attack management. The Long-term prophylaxis reduces attacks frequency, therefore the related costs by ~94% vs on demand treatment, resulting in a ~45% reduction in total annual direct medical costs per patient.
CONCLUSIONS: HAE imposes a significant economic burden on Mexico’s public healthcare system, primarily due to unpredictable acute attacks. Long-term prophylaxis substantially reduces healthcare costs and improves resource efficiency by reducing the frequency of angioedema attacks supporting its adoption as a cost-effective strategy.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE385
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Rare & Orphan Diseases